Physician profile

James Lew

Family Medicine · Salinas, CA

NPI 1629177506

$9,739.49

in general payments reported to CMS, 2019-2025

44 companies · $1,614 in 2025

The $1,614 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,826.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,215.18 2019-2025
Novo Nordisk INC $1,109.31 2019-2025 Ozempic, Rybelsus, Wegovy
Boehringer Ingelheim Pharmaceuticals, INC. $996.92 2019-2025 Jardiance
Lilly USA, LLC $977.34 2019-2025 Mounjaro, Jardiance, Zepbound
Glaxosmithkline, LLC. $808.32 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Amgen INC. $739.81 2019-2025 Evenity, Repatha, Otezla
Astrazeneca Pharmaceuticals Lp $682.12 2019-2025 Airsupra, Farxiga
Pfizer INC. $513.54 2019-2025
Abbott Laboratories $402.98 2022-2023 Freestyle Libre 3
Bayer Healthcare Pharmaceuticals INC. $299.94 2023-2025
Sanofi-Aventis U.S. LLC $264.54 2019-2025
Allergan, INC. $227.91 2019-2020
Idorsia Pharmaceuticals US INC $190.52 2023 Quviviq
Mylan Specialty L.P. $188.49 2023-2024 Yupelri
Janssen Pharmaceuticals, INC $165.41 2019-2022
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $119.20 2019-2023 Gardasil 9, Pneumovax 23, Vaxneuvance
Dexcom, INC. $99.97 2022-2025 Dexcom G6 Transmitter
Vifor Pharma, INC. $85.47 2021
Biohaven Pharmaceuticals, INC. $66.46 2021
Biohaven Pharmaceutical Holding Company Ltd. $63.68 2022
E.R. Squibb & Sons, L.L.C. $44.69 2025 Eliquis
Sunovion Pharmaceuticals INC. $38.94 2020-2022
Viiv Healthcare Company $33.03 2025 Apretude
Exact Sciences Corporation $32.78 2025 The Cologuard Plus Collection Kit
Organon LLC $31.52 2023 Nexplanon, Jada System
Radius Health, INC. $30.34 2019
Roche Diagnostics Corporation $27.53 2019-2021
Shire North American Group INC $24.98 2019
Amarin Pharma, INC. $21.57 2019
Gilead Sciences, INC. $20.70 2020
Astellas Pharma US INC $19.34 2019
Kyowa Kirin, INC. $18.83 2024 Nourianz
Phadia US INC. $18.74 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $17.95 2024 Xifaxan
Arbor Pharmaceuticals, INC. $17.94 2019
Philips North America LLC $17.93 2019
Ultragenyx Pharmaceutical INC. $16.38 2023
Coopersurgical, INC. $13.67 2020
Teva Pharmaceuticals USA, INC. $13.19 2023 Ajovy
Therapeuticsmd, INC. $12.99 2019
Takeda Pharmaceuticals U.S.A., INC. $12.73 2022
Hologic Sales and Service, LLC $12.63 2019
Sanofi Pasteur INC. $12.02 2021
Horizon Therapeutics Plc $11.96 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Lew

$9,739.49

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $1,614 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/164725/james-lew

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.